ACE 抑制剂通过降低老年阿尔茨海默病患者的肠道透性来提高运动和肌肉强度
Rizwan Qaisar1,2,3, Asima Karim1, M Shahid Iqbal4
1Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
Pharmaceuticals (Basel, Switzerland)
|February 27, 2026
概括
ангиотензин转化酶 (ACE) 抑制剂可以通过减少肠道通透性和炎症来改善阿尔茨海默病 (AD) 患者的身体功能. 这表明肠-血管-肌肉联系影响了AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压在阿尔茨海默病 (AD) 中普遍存在,并加剧功能衰退.
- ACE 抑制剂对阿尔茨海默病患者的肠道透性和身体能力的影响尚不清楚.
研究的目的:
- 调查肠道透性,身体能力和高血压阿尔茨海默病患者的ACE抑制剂使用之间的关系.
- 探索ACE抑制剂与其他抗高血压药物对AD的身体表现标志物和肠道屏障功能的影响.
主要方法:
- 长度研究比较高血压阿尔茨海默病患者服用ACE抑制剂 (n=55) 或其他抗高血压药物 (n=57),高血压阿尔茨海默病患者 (n=61) 和对照组 (n=64).
- 在基线和一年内,测量包括血阳素 (肠道透性),手握强度 (HGS) 和短物理性能电池 (SPPB).
- 评估了血C-反应蛋白和8-异质作为炎症和氧化应激的标志物.
主要成果:
- 与对照组相比,阿尔茨海默病患者的身体功能较差,血阳素含量较高.
- 在AD患者中使用ACE抑制剂与改善的HGS,步行速度和降低的血zonulin有关.
- 其他抗高血压药物治疗的阿尔茨海默病患者显示佐努林增加和HGS减少,而步行速度或SPPB没有变化.
- ACE 抑制剂还减少了炎症和氧化应激的标志物.
结论:
- ACE 抑制剂可能会提高高血压阿尔茨海默病患者的身体表现,可能是通过改善 perfusion 的血管效应.
- 这些机制可能间接有利于肠道屏障和肌肉功能,这表明肠-血管-肌肉轴.
- ACE 抑制剂代表了一种潜在的治疗策略,用于改善阿尔茨海默病的身体能力.
关键词:
ACE 抑制剂 是 一种 ACE 抑制剂.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.SPPBB SPPB 这是一个很好的选择.手握的强度和手握的强度.这种高血压,高血压.这里是 zonulin zonulin 的位置.更多相关视频
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
13.3K
07:21Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
1.6K
相关概念视频
01:15Drug Dosing: Geriatric Patients
327
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
327
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
284
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
284
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
299
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
299
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273